rf"\rn nffir-a• LJ 1 7,,~..-11.....i ...... 111"" r'-..........,,.........,,,,.,...a~1 r',....,....,._,.... J/,....:t ........... L- r">-1--·- t..1- -· r-'\_11_• AA"- r\A'°'

... ~u A..--'-. ~ - --- - . )'

N.S. arameswaran "-..._~'0 Managing Director ~ ~ DIN:00091097 ~

Wvv * ·<>x •

I

~ For Mesco Pharmaceuticals Limited

Due to losses in current year, we further wish to intimate that Board has not recommended any dividend for the Financial Year ended 31st March, 2018

3) Declaration pursuant to Regulation 33(3)(d) of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015

1) Audited financial results and statement of asset and liabilities for the quarter and financial year ended on 31st March, 2018 in a duly convened

2) Auditors Report on the financial results issued by the Statutory Auditors of the Company for the Financial year ended 31st March, 2018.

Pursuant to the Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) R~gulations, 2015 please find enclosed herewith following approved at the meeting of Board of Directors held on Wednesday, 30th May, 2018 commenced at 4.00 P.M. concluded at 5.30 P.M.

Dear Sir,

SCRIP CODE: 500274

Sub: Intimation under Regulation 30 and 33 SEBI(Listing Obligations and Disclosure Requirements) Regulations, 2015

30TH May, 2018 To, The General Manager Listing Operation, BSE Limited, Phiroze Jeejeebhoy Towers Dalal Street Mumbai - 400001

Corporate Identity No. L24111UR1986PLC015895 Regd. Office: Upper Kesalton, Tallital, Nainital-263 001, Uttarakhand,

W: www.mescopharma.com E-mail: nsparameswaran@mescosteel.com, Tel: 9871862796

IVIESCO PHARMACEUTICALS LIMITED

STATElVIENT OF STANDALONE AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2018 (Figures in Rs.)

Part -1 Quarter ended Year ended

Particulars 31.03.2018 31.12.2017 31.03.2017 31.03.2018 31.03.2017 (Audited) (Un-Audited) (Audited) (Audited) (Audited)

I Revenue From Operations - - - ~ - - II Other Income - - - - - m Total Income (I+ ll) - - - - -

EXPENSES Cost of materials consumed - - - - - Purchase of Stock-in Trade - - - - -

rv Changes in inventories of finished goods, Stock-in-Trade and work-in-progress - - - - - Employee benefits expense 75,000 74,194 177,500 305,58 I 374,505 Finance Cost - - - 150 - Depreciation and amortisation expense - - - - - Other Expenses 54,560 32,792 2,164,354 567.759 2,205.464

Total Expenses (IV) 129,560 106,986 2,341 ,854 873,490 2,579,969 v Profi\/(loss) before exceptional items and tax (I-IV) (129,560) (106,986) (2,341,854) (873,490) (2,579,969) Vl Exceptional items - - - - - VII Profit/(Loss) Before Tax (V-VI) (129,560) (106,986) (2,341,854) (873,490) (2,579,969)

Tax Expense: VIII (l) Current Tax - - 9,705 - 9.705

(2) Deferred Tax - - - - ~ [)( Profit/(Loss) for the period from Continuing Operations (VII-VII[) (129,560) (106,986) (2,351,559) (873,490) (2,589,674) x Profit/(Loss) from discontinued Operations - - - - - XI Tax expense of discontinued operations - - - - - Xll Profit/(loss) from Discontinued operations (after tax )(X+XI) - - - - - xrn Profit/(Loss) for the period (L"X+XIJ) (129,560) (106,986) (2,351,559) (873,490) (2,589,674)

Other Comprehensive Income A(i) Items that wiJJ not be reclassified to profit or loss

XIV (ii) Income tax relating to items that will not be reclassified to profit or loss - - - - - B(i) Items that will be reclassified to profit or loss . (ii) Income tax relating to items that will be reclassified to profit or loss

xv Total Comprehensive Income for the period (XIU+XIV) (Comprising Profit(Loss) and Other Comnrehensive Income for the neriod) (129,560) (106,986) (2,351.559) (873,490) (2,589,674)

XVI Earnings/(Loss) Per Equity Share (for continuing operation): Basic and Diluted (face value of Rs. I 0 each) 197,381,000 197,381,000 197,381,000 197,381.000 I 97.381,000

XVII Earnings/(Loss) Per Equity Share (for discontinued operation): Basic and Diluted (face value of Rs. I 0 each) - - - - -

xvm Earnings/(Loss) Per Equity Share (for discontinued and Continuing operation): ~ .. I'-

Basic and Diluted (face value of Rs. I 0 each) (0.01) (0.01) (0.12) rs»: (O.il4i / (0.13)

\_~ * §V ·~

l\JESCO PHARMACEUTICALS LIMrTED GIN: L24111UR1986PLC015895

REGO.OFFICE: UPPER KESALTON, TALLITAL, NAINITAL-263 001, UTTARAKHAND Tel. :+91-9871862796, W: www.mesopharma.com; E-mail : nsparameswaran@mescosteel.com

Date : 30.05.2018 Place : New Delhi

For and on Behalf of Board of Directors of Mesco Pharmaceuticals Limited

Notes 1) The Company has adopted Indian Accounting Standards (IND AS) prescribed under the Companies Act, 2013 read with relevant rules thereunder, with effect from April I, 2017 and accordingly these financial results have been prepared in accordance with the measurement and recognition principles laid down in Ind AS 34 Interim Financial Reporting prescribed under section 133 of the Companies Act, 2013 read with relevant rules made thereunder

2) The results for Quarter and Financial Year ended on March 31, 2018 presented here are Ind-AS Compliant and Audited by the Statutory Auditors of the Company

3) The above audited financial results for the quarter and year ended on March 31, 2018 have been reviewed by the Audit Committee and have been approved by the Board of Directors in its meeting held on May 30, 2018

4) The figures for the quarters ended March 31, 2018 are the balancing figures between the audited figures in respect of the full financial year and the published figures of nine months ended December 31. 20 I 7 which were subject to limited review by the statutory Auditors of the Company - '-"

5) Previous year period figures have been rearranged and regrouped wherever necessary to make them comparable with current period figures.

6) There were no manufacturing activities in the Company during the period under consideration

7) Statement of Reconciliation for net profit under lND AS and Indian GAAP for the quarter and year ended March 31, 2017: Quarter ended Year ended

Particulars March 31, 2017 March 31, 2017 (Rs.) (Rs.)

Net profit /(Loss) after tax for the period as per Indian GAAP (2,351,559) (2,589,674) Addi Less: Adjustments for GAAP Differences .

0 0 Net profit/ (Loss) after tax (before OCI) as per lND AS (2,351,559) (2,589,674) Other Comprehensive Income 0 0 Total Comprehensive Income/Loss for the period under Ind AS (2,351,559) (2.589,674) 8) Statement of Reconciliation of Equity as per GAAP and Ind-AS for the Previous year ended March 31, 2017 ,

I Particulars Year ended

March 31, 2017

Total Equity as per Previous GAAP 197.381.000 Adjustments relating to Ind-AS - Total Adjustments relating to Ind-AS - Total Equity as per Ind-AS

r- I

197 ,381.000

Date· 30 05.2018 Place· New Delhi

For and on Behalf of Board of Directors of

Mcsco Pharmaceuticals Limited CIN: L24111UR1986PLC015895

REGO.OFFICE : UPPER KESALTON, TALLITAI,., NAINITAL-263 001, UTTARAKHAND Tel. :+91-9871862796, W: www.mesopharma.com; E-mail : nsparameswaran@mescosteel.com

Statement of Assets & Liabilities (Figures in Rs.)

S.No Particulars As at 31st March, As at 31st March, 2018 2017

I 2 3 4 ASSETS

(I) Non-Current Assets (a) Property, Plant and Equipment 1,798,761 1,798,761 (b) Capital work-in-progress - - (c) Investment Property - - (d) Goodwill - - (e) Other Intangible assets - - (I) Intangible assets under development - - (g) Biological Assets other than bearer plants - - (h) Financial Assets

(i) Investments - - (ii) Trade receivables - - (iii) Loans - - (iv) Others (to be specified) 285,000 285,000

(i) Deferred tax assets (net) - - (j) Other non-current assets 1,800 -

(2) Current Assets . (a) Inventories - (b) Financial Assets

(i) Investments - - (ii) Trade receivables - - (iii) Cash and cash equivalents 395,918 394,768 (iv) Bank balances other th~m (iii) above - - (v) Loans - - (vi) Others (to be speci fied) - -

( c ) Current Tax Assets (Net) - - (d) Other current assets - -

Total Assets 2,481,479 2,478,529 EQUITY AND LIABILITIES Equity . (a) Equity Share capital 197,381,000 197 ,381,000 (b) Other Equity (302,431,993) (301,558,502) LIABILITIES

(I) Non-Current Lia bilitics (a) Financial Liabilities

(i) Borrowings I 07,461,040 106,579,937 (ii) Trade payables - - (iii) Other financial liabilities (other than

those specified in item (b), to be specified) - -

(b) Provisions - - (c) Deferred tax liabilities (Net) - - (d) Other non-current liabilities - -

(2) Current Liabilities (a) Financial Liabilities

(i) Borrowings - - - (ii) Trade payables 71,000 73,595 (iii) Other financial liabilities (other than

those specified in item (c )) - - (b) other current liabilities - - (c) Provisions 432 2,500 (d) Current Tax Liabilities (Net) - -

Total Equity and Liabilities 2,481,479 2,478,529

Corp. office: H-1, Zamrudpur Community Centre, Kai lash Colony, New Delhi- 110 048 Tel.: 011-29241099, 40587083

I

..a I' •

For Mesco Pharmaceuticals Limited

N.S. Pa~1~ ..__, Managing Director DIN: 00091097

This declaration is issued in compliance of Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended by SEBI (Listing Obligations and Disclosure Requirements) (Amendment) Regulations, 2016 vide notification no. SEBI/LAD­ NRO/GN/2016-17/001 dated 25/05/2016.

I, N.S. Parameswaran (DIN: 00091097), Managing Director of Mesco Pharmaceuticals Limited (SCRIP CODE: 500274 hereby declare that the Statutory Auditors of the Company, M/s. Sangram Paul & Co. (FRN 308001E) have issued an Audit Report as per Regulation 33 of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 with unmodified opinion on the financial results of the Company for the quarter ended and financial year ended on 31st of March, 2018.

Sub: Declaration pursuant to Regulation 33(3)(d) of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015

30'" May, 2018 To, Department of Corporate Services BSE Limited, Phiroze Jeejeebboy Towers Dalal Street Mumbai - 400001

Corporate Identity No. L24111UR1986PLC015895 Regd. Office: Upper Kesalton, Tallital, Nainital-263 001, Uttarakhand,

W: www.mescopharma.com E-mail: nsparameswaran@mescosteel.com, Tel: 9871862796

MESCO PHARMACEUTICALS LIMITED

Scanned by CamScanner

Jn our opinion and to the best of our information and according to the explanations give~ to us these quarterly

financial results as well as the financial year ended results:

We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards

require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are

free of material misstatement(s). An audit includes examining, on a test basis, evidence supporting the amounts

disclosed as financial results. An audit also includes assessing the accounting principles used and significant

estimates made by management. We believe that our audit provides a reasonable basis for our opinion.

Figures for the quarter ended March 31, 2018 as reported in these financial results are the balancing figures

between audited figures in respect of the full financial year and the published year to date figures upto the end

of the third quarter of the current financial year. Figures upto the end of third quarter for the current financial

year had only been reviewed by us and not subjected to audit.

These financial results have been prepared in accordance with the recognition and measurement principles laid

down in India Accounting Standards (IND-AS) prescribed under Section 133 of the Companies Act, 2013 ('the

Act') read with relevant rules issued thereunder and other accounting principles generally accepted in India and

other recognized accounting practices and policies and in compliance with Regulation 33 of SEBI (Listing

Obligations & Disclosure Requirements) Regulations, 2015 as modified by Circular No.

CIRJCFD/FAC/62/2016 dated July 05, 2016 issued by SEBI which is the responsibility of the company's

management. Our responsibility is to express an opinion on these financial results based on our audit of these

standalonefinancial statement.

We have audited the Financial Results ofMESCO PHARMACEUTICALS LIMITED for the quarter ended 31"

March, 2018 and for the financial year starting from I" April, 20 I 7to 31 •1 March, 2018, attached herewith, being

submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and

Disclosure Requirements) Regulations, 2015.

To, Board of Directors Mesco Pharmaceuticals Limited

INDEPENDENT AUDITOR'S REPORT

Sangram Paul & Co. Chartered Accountants

Pio\ tlo 754115. Jayaoe·11/1na1. Bnuballc~"ar-751 013 PhQne 067~·23€.085~ llob 933111&878

S.K.Paul. F.C.A Chartered Accountant

Scanned by CamScanner

• ..

I

Pince: New lklhl Date: J0.05.2018

For Sangram Paul & Co.

The Comparative financial information for the quarter and full financial year ended ~larch JI, 2017 included in

the Statement is based on previously published standalone financial results for the said periods prepared in

accordance with the Companies (Accounting Standards) Rules, 2006 and other accounting principles generally

accepted in India audited by Mis N. Dhawan& Co., Chartered Accountants whose report dared 30.05.2017

expressed an unmodified opinion on those standalone financial results, as adjusted for the differences in the

accounting principles adopted by the Company on transition to lnd-/\S, which have been audited by us.

(i) arc .prescnted in accordance with thc.rcquircmcms CJf Rcgulatiou J.l of the SUIJ Ir i\t1nr < >bf1r,111,,n,

and Disclosure Requirements) Rcgulatior», 2015 in 1his regard :t\ modified hy Circul.ir ~n

CIR/CFD/FCA/62/2016 dated July 05, 2016 issued by SElll: and

(ii) give a true and fair view of the net profit/net lo5s( for quarter) ;111d net profillnct los~ (for full financial

year) and other financial information for the quarter ended 31" March, 2018.u \.\ell :ti the full fin:rnci.11

year results for the period from I" April. 2017 to JI'' March. 20 IR.

I,